Minority Views
[To accompany H.R. 3290]
The Committee on Energy and Commerce, to whom was referred
the bill (H.R. 3290) to amend title III of the Public Health
Service Act to ensure transparency and oversight of the 340B
drug discount program, having considered the same, reports
favorably thereon with an amendment and recommends that the
bill as amended do pass.
CONTENTS
Page
Purpose and Summary.............................................. 4
Background and Need for Legislation.............................. 4
Committee Action................................................. 4
Committee Votes.................................................. 5
Oversight Findings and Recommendations........................... 7
New Budget Authority, Entitlement Authority, and Tax Expenditures 7
Congressional Budget Office Estimate............................. 7
Federal Mandates Statement....................................... 7
Statement of General Performance Goals and Objectives............ 7
Duplication of Federal Programs.................................. 7
Related Committee and Subcommittee Hearings...................... 7
Committee Cost Estimate.......................................... 7
Earmarks, Limited Tax Benefits, and Limited Tariff Benefits...... 8
Advisory Committee Statement..................................... 8
Applicability to Legislative Branch.............................. 8
Section-by-Section Analysis of the Legislation................... 8
Changes in Existing Law Made by the Bill, as Reported............ 8
Minority Views................................................... 21
The amendment is as follows:
Strike all after the enacting clause and insert the
following:
SECTION 1. SHORT TITLE.
This Act may be cited as the ``340B Transparency Act''.
SEC. 2. ENSURING TRANSPARENCY AND OVERSIGHT OF THE 340B DRUG DISCOUNT
PROGRAM.
(a) In General.--Section 340B(a)(5) of the Public Health Service Act
(42 U.S.C. 256b(a)(5)) is amended--
(1) in subparagraph (C)--
(A) by striking ``A covered entity shall permit'' and
inserting:
``(i) Duplicate discounts and drug resale.--A
covered entity shall permit''; and
(B) by adding at the end the following new clauses:
``(ii) Use of savings.--A covered entity
shall permit the Secretary to audit, at the
Secretary's expense, the records of the entity
to determine--
``(I) how savings (as defined in
subparagraph (E)(iv)) from covered
outpatient drugs subject to an
agreement under this section furnished
by such entity are used by such entity;
and
``(II) such entity's compliance with
subparagraph (E).
``(iii) Records retention.--Covered entities
shall retain such records and provide such
records and reports as determined necessary by
the Secretary for carrying out this
subparagraph.''; and
(2) by adding at the end the following new subparagraph:
``(E) Reporting.--
``(i) In general.--During the first year
beginning on or after the date that is 14
months after the date of enactment of this
subparagraph and during each subsequent year,
each covered entity described in subparagraph
(L) of paragraph (4) (and any other covered
entity specified by the Secretary) shall report
to the Secretary (at a time and in a form and
manner specified by the Secretary) the
following information with respect to the
preceding year:
``(I) With respect to such covered
entity and each off-campus outpatient
department, as applicable, of such
entity--
``(aa) the total number of
individuals who were dispensed
or administered covered
outpatient drugs during such
preceding year that were
subject to an agreement under
this section; and
``(bb) the number of such
individuals described in a
category specified in clause
(iv), broken down by each such
category.
``(II) With respect to such covered
entity and each off-campus outpatient
department, as applicable, of such
entity--
``(aa) the percentage of the
total number of individuals
furnished items and services
during such preceding year who
were dispensed or administered
covered outpatient drugs during
such preceding year that were
subject to an agreement under
this section; and
``(bb) for each category
specified in clause (iii), the
percentage of the total number
of individuals described in
such category furnished items
and services during such
preceding year who were
dispensed or administered
covered outpatient drugs during
such preceding year that were
subject to an agreement under
this section.
``(III) With respect to such covered
entity and each off-campus outpatient
department, as applicable, of such
entity, the total costs incurred during
the year at each such site and the cost
incurred at each such site for charity
care (as defined in line 23 of
worksheet S-10 to the Medicare cost
report, or in any successor form).
``(IV) With respect to such covered
entity and each off-campus outpatient
department, as applicable, of such
entity, the costs incurred during the
year of furnishing items and services
at each such department to patients of
such entity who were entitled to
benefits under part A of title XVIII of
the Social Security Act or enrolled
under part B of such title, enrolled in
a State plan under title XIX of such
Act (or a waiver of such plan), or who
were uninsured for services, minus the
sum of--
``(aa) payments under title
XVIII of such Act for such
items and services (including
any cost sharing for such items
and services);
``(bb) payments under title
XIX of such Act for such items
and services (including any
cost sharing for such items and
services); and
``(cc) payments by uninsured
patients for such items and
services.
``(V) With respect to such covered
entity and each off-campus outpatient
department, as applicable, of such
entity, savings (as defined in clause
(iv)) from covered outpatient drugs
subject to an agreement under this
section furnished by such entity or
department.
``(ii) Publication.--The Secretary shall
publish data reported under clause (i) with
respect to a year annually on the public
website of the Department of Health and Human
Services in an electronic and searchable
format, which may include the 340B Office of
Pharmacy Affairs Information System (or a
successor to such system), in a manner that
shows each category of data reported in the
aggregate and identified by the specific
covered entity submitting such data. The
Secretary shall include in such publication the
disproportionate patient percentage (as defined
in section 1886(d)(5)(F)(vi) of the Social
Security Act) of each such covered entity (if
applicable) for each cost reporting period
occurring during such year.
``(iii) Categories specified.--For purposes
of clause (i), the categories specified in this
clause are the following:
``(I) Individuals covered under a
group health plan or group or
individual health insurance coverage
(as such terms are defined in section
2791).
``(II) Individuals entitled to
benefits under part A or enrolled under
part B of title XVIII of the Social
Security Act.
``(III) Individuals enrolled under a
State plan under title XIX of such Act
(or a waiver of such plan).
``(IV) Individuals enrolled under a
State child health plan under title XXI
of such Act (or a waiver of such plan).
``(V) Individuals not described in
any preceding subclause and not covered
under any Federal health care program
(as defined in section 1128B of such
Act but including the program
established under chapter 89 of title
5, United States Code).
``(iv) Definitions.--For purposes of this
subparagraph:
``(I) Off-campus outpatient
department.--The term `off-campus
outpatient department' means a
department of a provider (as defined in
section 413.65 of title 42, Code of
Federal Regulations, or any successor
regulation) that is not located--
``(aa) on the campus (as
defined in such section) of
such provider; or
``(bb) within the distance
(described in such definition
of campus) from a remote
location of a hospital facility
(as defined in such section).
``(II) Savings.--The term `savings'
means, with respect to a covered
outpatient drug purchased by a covered
entity, the difference between--
``(aa) the price for such
drug that such entity would
have otherwise paid for such
drug obtained through a group
purchasing organization or
other group purchasing
arrangement had the requirement
described in paragraph
(4)(L)(iii) not applied (or, in
the case such entity would not
have obtained covered
outpatient drugs through such
an organization or arrangement
had such requirement not
applied or information to
determine such price that such
entity would have so otherwise
paid is not available, the
wholesale acquisition cost (as
defined in section
1847A(c)(6)(B) of the Social
Security Act) for such drug);
and
``(bb) the ceiling price for
such drug.''.
(b) Enforcement.--Section 340B(d)(2)(B) of the Public Health Service
Act (42 U.S.C. 256b(d)(2)(B)) is amended by adding at the end the
following new clause:
``(vi) The imposition of civil monetary
penalties in amounts determined appropriate by
the Secretary in the case that the Secretary
determines that a covered entity is not in
compliance with subsection (a)(5)(E) .''.
(c) Rulemaking.--Not later than 180 days after the date of the
enactment of this Act, the Secretary of Health and Human Services shall
issue an interim final rule to carry out section 340B(a)(5)(E) of the
Public Health Service Act, as added by subsection (a)(2).
Purpose and Summary
This bill requires disproportionate share hospitals (DSH)
hospitals participating in the Public Health Service Act's
``340B'' Drug Discount Program to report on net savings from
the Program and other relevant metrics.
Background and Need for Legislation
The 340B Drug Discount Program provides for opportunities
for covered entities in the Program to purchase drugs at
discounts and to receive reimbursements for the drugs at
standard prices, thus allowing for the covered entity to
receive reimbursements in excess of what the covered entity
would have otherwise received without participation in the
Program. In providing additional revenue to covered entities,
the Program allows for covered entities to provide additional
resources to patients and their communities at a loss.
In recent years, the 340B Program has come under fire for
the opacity of its size and scope and the potential for its
lucrative savings to encourage consolidation in the health care
sector as hospitals seek to expand their 340B footprint. While
some estimates claim that the Program is worth about $30-$60
billion per year, there is little data to verify the accuracy
of this claim or the allegations that the Program furthers
consolidation. Furthermore, there is no standardized reporting
to understand the usages of the Program and what value the
Program brings to respective covered entities.
As such, the bill would require standardized of the size
and scope of the Program for DSH hospitals that participate in
the Program, and it would allow for the Secretary to increase
reporting requirements for additional covered entities beyond
just DSH hospitals. Among the reporting requirements in the
bill are requirements to disclose a covered entity's net
savings from the Program, a covered entity's patient mix, a
covered entity's charity care, and a covered entity's payer
shortfall (including reporting for all relevant categories at
respective, outpatient facilities for a covered entity). The
bill would also establish civil monetary penalties for
noncompliance.
Committee Action
On April 26, 2023, the Subcommittee on Health held a
hearing on H.R. 3290. The title of the hearing was ``Lowering
Unaffordable Costs: Legislative Solutions to Increase
Transparency and Competition in Health Care.'' The Subcommittee
received testimony from:
Ashley Thompson, Senior Vice President,
Public Policy Analysis and Development, American
Hospital Association.
On May 17, 2023, the Subcommittee on Health met in open
markup session and forwarded H.R. 3290 as amended, to the full
Committee by a recorded vote of 16 yeas and 12 nays.
On May 24, 2023, the full Committee on Energy and Commerce
met in open markup session and ordered H.R. 3290, as amended,
favorably reported to the House by a recorded vote of 29 yeas
and 22 nays.
Committee Votes
The following reflects the record votes taken during the
Committee consideration:
[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]
Oversight Findings and Recommendations
Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of
rule XIII, the Committee held a hearing and made findings that
are reflected in this report.
New Budget Authority, Entitlement Authority, and Tax Expenditures
Pursuant to clause 3(c)(2) of rule XIII, the Committee
finds that H.R. 3290 would result in no new or increased budget
authority, entitlement authority, or tax expenditures or
revenues.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to ensure
transparency and oversight of the 340B Drug Discount Program.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 3290 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
hearing was used to develop or consider H.R. 3290:
On April 26, 2023, the Subcommittee on
Health held a hearing on H.R. 3290. The title of the
hearing was ``Lowering Unaffordable Costs: Legislative
Solutions to Increase Transparency and Competition in
Health Care.'' The Subcommittee received testimony
from:
Ashley Thompson, Senior Vice
President, Public Policy Analysis and
Development, American Hospital Association.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmarks, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 3290 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides a short title of the ``340B Transparency
Act.''
Section 2. Ensuring transparency and oversight of the 340B drug
discount program
Section 2 would require DSH hospitals participating in the
340B Program, as well as the covered entity's respective
outpatient facilities, to report certain information. The
information that must be reported includes: the net savings
from the 340B Program for the covered entity; the patient mix
for the covered entity; the charity care for the covered
entity; and the payer shortfall for the covered entity.
In addition, section 2 would permit the Secretary to expand
reporting requirements to additional covered entities beyond
just DSH hospitals. It would also establish civil monetary
penalties for covered entities not in compliance with the law.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
PUBLIC HEALTH SERVICE ACT
* * * * * * *
TITLE III--GENERAL POWERS AND DUTIES OF PUBLIC HEALTH SERVICE
* * * * * * *
Part D--Primary Health Care
* * * * * * *
Subpart VII--Drug Pricing Agreements
limitation on prices of drugs purchased by covered entities
Sec. 340B. (a) Requirements for Agreement With Secretary.--
(1) In general.--The Secretary shall enter into an
agreement with each manufacturer of covered outpatient
drugs under which the amount required to be paid
(taking into account any rebate or discount, as
provided by the Secretary) to the manufacturer for
covered outpatient drugs (other than drugs described in
paragraph (3)) purchased by a covered entity on or
after the first day of the first month that begins
after the date of the enactment of this section, does
not exceed an amount equal to the average manufacturer
price for the drug under title XIX of the Social
Security Act in the preceding calendar quarter, reduced
by the rebate percentage described in paragraph (2).
Each such agreement shall require that the manufacturer
furnish the Secretary with reports, on a quarterly
basis, of the price for each covered outpatient drug
subject to the agreement that, according to the
manufacturer, represents the maximum price that covered
entities may permissibly be required to pay for the
drug (referred to in this section as the ``ceiling
price''), and shall require that the manufacturer offer
each covered entity covered outpatient drugs for
purchase at or below the applicable ceiling price if
such drug is made available to any other purchaser at
any price.
(2) Rebate percentage defined.--
(A) In general.--For a covered outpatient
drug purchased in a calendar quarter, the
``rebate percentage'' is the amount (expressed
as a percentage) equal to--
(i) the average total rebate required
under section 1927(c) of the Social
Security Act with respect to the drug
(for a unit of the dosage form and
strength involved) during the preceding
calendar quarter; divided by
(ii) the average manufacturer price
for such a unit of the drug during such
quarter.
(B) Over the counter drugs.--
(i) In general.--For purposes of
subparagraph (A), in the case of over
the counter drugs, the ``rebate
percentage'' shall be determined as if
the rebate required under section
1927(c) of the Social Security Act is
based on the applicable percentage
provided under section 1927(c)(3) of
such Act.
(ii) Definition.--The term ``over the
counter drug'' means a drug that may be
sold without a prescription and which
is prescribed by a physician (or other
persons authorized to prescribe such
drug under State law).
(3) Drugs provided under state medicaid plans.--Drugs
described in this paragraph are drugs purchased by the
entity for which payment is made by the State under the
State plan for medical assistance under title XIX of
the Social Security Act.
(4) Covered entity defined.--In this section, the
term ``covered entity'' means an entity that meets the
requirements described in paragraph (5) and is one of
the following:
(A) A Federally-qualified health center (as
defined in section 1905(l)(2)(B) of the Social
Security Act).
(B) An entity receiving a grant under section
340A.
(C) A family planning project receiving a
grant or contract under section 1001.
(D) An entity receiving a grant under subpart
II of part C of title XXVI (relating to
categorical grants for outpatient early
intervention services for HIV disease).
(E) A State-operated AIDS drug purchasing
assistance program receiving financial
assistance under title XXVI.
(F) A black lung clinic receiving funds under
section 427(a) of the Black Lung Benefits Act.
(G) A comprehensive hemophilia diagnostic
treatment center receiving a grant under
section 501(a)(2) of the Social Security Act.
(H) A Native Hawaiian Health Center receiving
funds under the Native Hawaiian Health Care Act
of 1988.
(I) An urban Indian organization receiving
funds under title V of the Indian Health Care
Improvement Act.
(J) Any entity receiving assistance under
title XXVI (other than a State or unit of local
government or an entity described in
subparagraph (D)), but only if the entity is
certified by the Secretary pursuant to
paragraph (7).
(K) An entity receiving funds under section
318 (relating to treatment of sexually
transmitted diseases) or section 317(j)(2)
(relating to treatment of tuberculosis) through
a State or unit of local government, but only
if the entity is certified by the Secretary
pursuant to paragraph (7).
(L) A subsection (d) hospital (as defined in
section 1886(d)(1)(B) of the Social Security
Act) that--
(i) is owned or operated by a unit of
State or local government, is a public
or private non-profit corporation which
is formally granted governmental powers
by a unit of State or local government,
or is a private non-profit hospital
which has a contract with a State or
local government to provide health care
services to low income individuals who
are not entitled to benefits under
title XVIII of the Social Security Act
or eligible for assistance under the
State plan under this title;
(ii) for the most recent cost
reporting period that ended before the
calendar quarter involved, had a
disproportionate share adjustment
percentage (as determined under section
1886(d)(5)(F) of the Social Security
Act) greater than 11.75 percent or was
described in section
1886(d)(5)(F)(i)(II) of such Act; and
(iii) does not obtain covered
outpatient drugs through a group
purchasing organization or other group
purchasing arrangement.
(M) A children's hospital excluded from the
Medicare prospective payment system pursuant to
section 1886(d)(1)(B)(iii) of the Social
Security Act, or a free-standing cancer
hospital excluded from the Medicare prospective
payment system pursuant to section
1886(d)(1)(B)(v) of the Social Security Act,
that would meet the requirements of
subparagraph (L), including the
disproportionate share adjustment percentage
requirement under clause (ii) of such
subparagraph, if the hospital were a subsection
(d) hospital as defined by section
1886(d)(1)(B) of the Social Security Act.
(N) An entity that is a critical access
hospital (as determined under section
1820(c)(2) of the Social Security Act), and
that meets the requirements of subparagraph
(L)(i).
(O) An entity that is a rural referral
center, as defined by section 1886(d)(5)(C)(i)
of the Social Security Act, or a sole community
hospital, as defined by section
1886(d)(5)(C)(iii) of such Act, and that both
meets the requirements of subparagraph (L)(i)
and has a disproportionate share adjustment
percentage equal to or greater than 8 percent.
(5) Requirements for covered entities.--
(A) Prohibiting duplicate discounts or
rebates.--
(i) In general.--A covered entity
shall not request payment under title
XIX of the Social Security Act for
medical assistance described in section
1905(a)(12) of such Act with respect to
a drug that is subject to an agreement
under this section if the drug is
subject to the payment of a rebate to
the State under section 1927 of such
Act.
(ii) Establishment of mechanism.--The
Secretary shall establish a mechanism
to ensure that covered entities comply
with clause (i). If the Secretary does
not establish a mechanism within 12
months under the previous sentence, the
requirements of section 1927(a)(5)(C)
of the Social Security Act shall apply.
(B) Prohibiting resale of drugs.--With
respect to any covered outpatient drug that is
subject to an agreement under this subsection,
a covered entity shall not resell or otherwise
transfer the drug to a person who is not a
patient of the entity.
(C) Auditing.--[A covered entity shall
permit]
(i) Duplicate discounts and drug
resale._A covered entity shall permit
the Secretary and the manufacturer of a
covered outpatient drug that is subject
to an agreement under this subsection
with the entity (acting in accordance
with procedures established by the
Secretary relating to the number,
duration, and scope of audits) to audit
at the Secretary's or the
manufacturer's expense the records of
the entity that directly pertain to the
entity's compliance with the
requirements described in subparagraphs
(A) or (B) with respect to drugs of the
manufacturer.
(ii) Use of savings.--A covered
entity shall permit the Secretary to
audit, at the Secretary's expense, the
records of the entity to determine--
(I) how savings (as defined
in subparagraph (E)(iv)) from
covered outpatient drugs
subject to an agreement under
this section furnished by such
entity are used by such entity;
and
(II) such entity's compliance
with subparagraph (E).
(iii) Records retention.--Covered
entities shall retain such records and
provide such records and reports as
determined necessary by the Secretary
for carrying out this subparagraph.
(D) Additional sanction for noncompliance.--
If the Secretary finds, after audit as
described in subparagraph (C) and after notice
and hearing, that a covered entity is in
violation of a requirement described in
subparagraphs (A) or (B), the covered entity
shall be liable to the manufacturer of the
covered outpatient drug that is the subject of
the violation in an amount equal to the
reduction in the price of the drug (as
described in subparagraph (A)) provided under
the agreement between the entity and the
manufacturer under this paragraph.
(E) Reporting.--
(i) In general.--During the first
year beginning on or after the date
that is 14 months after the date of
enactment of this subparagraph and
during each subsequent year, each
covered entity described in
subparagraph (L) of paragraph (4) (and
any other covered entity specified by
the Secretary) shall report to the
Secretary (at a time and in a form and
manner specified by the Secretary) the
following information with respect to
the preceding year:
(I) With respect to such
covered entity and each off-
campus outpatient department,
as applicable, of such entity--
(aa) the total number
of individuals who were
dispensed or
administered covered
outpatient drugs during
such preceding year
that were subject to an
agreement under this
section; and
Minority Views
H.R. 3290 will provide information that will obscure how
the 340B program works and misconstrue the value of the program
to patients rather than provide transparency into the program.
The legislation would require hospitals that participate in
the 340B program to report on the savings they receive from the
program and compare that with their costs for charity care, or
costs incurred for caring for Medicaid and Medicare patients
and the uninsured. However, reports would not include
opportunities for covered entities to explain other ways they
use savings to expand care. Covered entities have voluntarily
shared that they use 340B savings to provide low-cost drugs to
patients, improve medication management, and help patients with
complex care needs get connected with specialists and social
services.\1\
---------------------------------------------------------------------------
\1\340B Health, 2021 340B Health Annual Survey: 340B Continues to
Support Essential Programs and Services in the Face of Significant
Financial Stress on Hospitals (https://www.340bhealth.org/files/
340B_Health_Survey_Report_2021_FINAL.pdf).
---------------------------------------------------------------------------
These activities all provide value and benefit for
patients, but would not necessarily be captured in the
reporting metrics listed in the bill. By limiting the view of
the program to just a narrow band of metrics, the reports
produced by this legislation could imply that the program is
not providing benefits.
The bill also fails to include transparency or program
integrity measures regarding participating pharmaceutical
manufacturers, at a time when many large drug companies are
openly violating the law by failing to deliver drugs to covered
entities' contract pharmacies.\2\ Pharmaceutical manufacturers'
failure to comply with the 340B statute is costing millions of
dollars to hospitals and other covered entities, and H.R. 3290
does nothing to address this issue.
---------------------------------------------------------------------------
\2\Fierce Pharma, AHA: Drugmaker 340B restrictions are harming
safety net hospitals financially (https://www.fiercehealthcare.com/
providers/aha-drug-maker-340b-restrictions-are-harming-safety-net-
hospitals-financially) (Nov. 15, 2022).
---------------------------------------------------------------------------
The Health Resources and Services Administration (HRSA),
the agency charged with overseeing the 340B program, already
has several requirements in place for covered entities,
including annual recertification, and audits of covered
entities for compliance with the law. This bill would expand
HRSA's responsibilities to further audit the use of covered
entities' savings. Unfortunately, the legislation includes no
additional resources for the agency to conduct these audits.
With only 23 staff overseeing the 340B program, additional
program integrity measures will require not only more
responsibilities, but more authority and resources.
H.R. 3290, as amended and passed by the Full Committee,
brings little transparency to the 340B program, and may make
the benefits of the program to patients and communities more
difficult to understand. It provides no additional resources
for audits or authorities to help bring program integrity to
the 340B program.
Frank Pallone, Jr.,
Ranking Member.
[all]